Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH
Image Credit: KK Stock/Shutterstock.com Consequently, researchers are investigating new pharmacotherapies, including those that target the glucagon-like peptide-1 (GLP-1) system
The Tesamorelin/Ipamorelin combination provides dual-pathway stimulation of growth hormone releaseGHRH receptor activation and ghrelin receptor activationresulting in: Visceral Fat Reduction & Body Composition Tesamorelin has been shown in clinical trials to significantly reduce visceral adipose tissue while preserving lean body mass, making it one of the most targeted GH-based therapies for central fat reduction
This is particularly beneficial in patients with concurrent type 2 diabetes or prediabetes Cardiovascular benefits: Clinical trial data, most notably the SELECT trial for semaglutide, have demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease (Lincoff et al., New England Journal of Medicine , 2023) Available GLP-1 Agents for Weight Loss The incretin-based weight management pharmacopeia has expanded rapidly
10.1016/j.foodres.2024.114508 219 ZhaoxiaW.SiyaoS.JiaqianJ.TanD.DonghuaJ.BingB.et al (2014)
In fact, clinical trials show tirzepatide can help people shed around 1520% of body weight when combined with diet and exercise
